These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
315 related items for PubMed ID: 2044637
1. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Chao Y, Chen JS, Hunt VM, Kuron GW, Karkas JD, Liou R, Alberts AW. Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637 [Abstract] [Full Text] [Related]
2. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST, Kalinowski SS, Schafer BL, Tanaka RD. J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [Abstract] [Full Text] [Related]
3. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW. Cardiology; 1990 Sep; 77 Suppl 4():14-21. PubMed ID: 2073667 [Abstract] [Full Text] [Related]
4. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Qin W, Infante J, Wang SR, Infante R. Biochim Biophys Acta; 1992 Jul 09; 1127(1):57-66. PubMed ID: 1627634 [Abstract] [Full Text] [Related]
5. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. Toxicol Appl Pharmacol; 1995 Mar 09; 131(1):163-74. PubMed ID: 7878672 [Abstract] [Full Text] [Related]
6. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. Cohen LH, van Vliet A, Roodenburg L, Jansen LM, Griffioen M. Biochem Pharmacol; 1993 Jun 09; 45(11):2203-8. PubMed ID: 8517861 [Abstract] [Full Text] [Related]
7. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells. Nagata Y, Hidaka Y, Ishida F, Kamei T. Biochem Pharmacol; 1990 Aug 15; 40(4):843-50. PubMed ID: 2167097 [Abstract] [Full Text] [Related]
8. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW. Metabolism; 2001 Oct 15; 50(10):1234-41. PubMed ID: 11586500 [Abstract] [Full Text] [Related]
9. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M, Rauli S, Galli Kienle M. Lipids; 1995 Nov 15; 30(11):1057-61. PubMed ID: 8569435 [Abstract] [Full Text] [Related]
10. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Biochim Biophys Acta; 1990 Jul 16; 1045(2):115-20. PubMed ID: 2116173 [Abstract] [Full Text] [Related]
11. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Yanagita T, Yamamoto K, Ishida S, Sonda K, Morito F, Saku K, Sakai T. Clin Ther; 1994 Jul 16; 16(2):200-8. PubMed ID: 8062316 [Abstract] [Full Text] [Related]
12. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. Arzneimittelforschung; 1997 Aug 16; 47(8):904-9. PubMed ID: 9296275 [Abstract] [Full Text] [Related]
13. Pharmacology of competitive inhibitors of HMG-CoA reductase. Corsini A, Maggi FM, Catapano AL. Pharmacol Res; 1995 Jan 16; 31(1):9-27. PubMed ID: 7784310 [No Abstract] [Full Text] [Related]
14. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Amin D, Gustafson SK, Weinacht JM, Cornell SA, Neuenschwander K, Kosmider B, Scotese AC, Regan JR, Perrone MH. Pharmacology; 1993 Jan 16; 46(1):13-22. PubMed ID: 8434028 [Abstract] [Full Text] [Related]
15. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin]. Mantell G. Therapie; 1992 Jan 16; 47(2):161-4. PubMed ID: 1412144 [Abstract] [Full Text] [Related]
17. Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients. Pazzucconi F, Franceschini G, Gianfranceschi G, Campagnoli G, Sirtori CR. Pharmacol Res; 1996 Jan 16; 34(3-4):131-3. PubMed ID: 9051704 [Abstract] [Full Text] [Related]
18. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M. Lab Anim; 1992 Oct 16; 26(4):269-80. PubMed ID: 1447905 [Abstract] [Full Text] [Related]
19. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Serajuddin AT, Ranadive SA, Mahoney EM. J Pharm Sci; 1991 Sep 16; 80(9):830-4. PubMed ID: 1800703 [Abstract] [Full Text] [Related]
20. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Huff MW, Burnett JR. Curr Opin Lipidol; 1997 Jun 16; 8(3):138-45. PubMed ID: 9211061 [Abstract] [Full Text] [Related] Page: [Next] [New Search]